Acusphere, Inc.
ACUS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$50
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $50.00 |
|---|---|
| Enterprise Value | $12.65 Million |
| Earnings per Share | $-12.6 |
| Beta | -0.45 |
| Outstanding Shares | 4,721,800 |
Return
| Return on Equity | 458.53% |
|---|---|
| Return on Assets | -207.81% |
| Return on Invested Capital | -1462.89% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 5.01 |
| Enterprise Value to EBIT | -0.27 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.32 |
| Debt to Equity | -1.62 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Acusphere, Inc.
50 employees
CEO: William I. Ramage D.Phil
Acusphere, Inc. is a pharmaceutical firm specializing in the creation and market launch of cardiovascular treatments. Its flagship product is Imagify (perflubutane polymer microspheres), a cardiovascular medication designed to assess myo...